We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Obstetrics and Gynecology

George R. Huggins, MD; Asha Rijhsinghani-Bhatia, MD
JAMA. 1990;263(19):2663-2665. doi:10.1001/jama.1990.03440190119063.
Text Size: A A A
Published online


During the past several years the development of gonadotropin-releasing hormone agonist (GnRH-a) therapy has provided the gynecologist with significant new therapies in infertility and general gynecology.

Perhaps 25% to 33% of female infertility is the result of ovulatory failure. The initiating problem may be located in one or multiple foci in the hypothalamic-pituitary-ovarian axis. Since 1971 when gonadotropin-releasing hormone (GnRH) was first isolated, numerous studies have demonstrated its value in diverse regimens designed to overcome ovulatory dysfunction. Gonadotropin-releasing hormone, located primarily in the hypothalamus, is normally released in a pulsatile fashion into the pituitary portal circulation, where it stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Despite intensive study and widespread availability, the use of GnRH has often proved disappointing in the induction of ovulation for patients with ovulatory dysfunction and for patients undergoing controlled ovarian hyperstimulation for in vitro fertilization/gamete intrafallopian transfer. Leuprolide ([D-Leu6, Pro


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.